一枚硬币,无需翻转:癌症与冠状动脉疾病共享的PET靶点
本文综述了PET示踪剂评估的癌症与冠状动脉疾病共同的生物学特征,聚焦于已用于临床及具有转化潜力的示踪剂,并讨论了PET在诊断、风险分层和治疗监测中的当前价值与预期贡献。结论认为,PET使用多种放射性示踪剂可增进对癌症与冠状动脉疾病共享病理生理变化的理解,有助于准确诊断、预后评估和管理决策。
要点
- 癌症与冠状动脉疾病存在共享的生物学特征,可用PET示踪剂进行评估。
- PET使用多种放射性示踪剂有助于两种疾病的诊断、风险分层和治疗监测。
- 随着治疗策略演变和新型特异性配体进入临床,PET的作用可能进一步增强。
核心结论
- PET使用多种放射性示踪剂可增进对癌症与冠状动脉疾病共享病理生理变化的理解,有助于准确诊断、预后评估和管理决策。
研究设计与样本
- 本文为综述,旨在回顾癌症与冠状动脉疾病经PET示踪剂评估的共同生物学特征,聚焦于已用于临床及具有转化潜力的示踪剂,并讨论PET在诊断、风险分层和治疗监测中的当前价值与预期贡献。
临床应用与阅片要点
- 作者认为,随着阻断两种疾病发生发展的治疗策略的演变以及新型特异性配体进入临床实践,PET可能在诊断、风险分层和治疗监测中发挥越来越强的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purposes of this article are to review the common biologic features of cancer and coronary artery disease assessed with PET tracers, focusing on those already used in the clinic and those with translational potential, and to discuss the current value and expected contribution of PET in diagnosis, risk stratification, and treatment monitoring.
CONCLUSION: PET using a wide variety of radiotracers enhances understanding of pathophysiologic changes shared by cancer and coronary artery disease, helps establish an accurate diagnosis, and aids in prognostic assessment and management decisions. It is likely that with the evolution of therapeutic strategies for blocking the development and progression of both diseases and with the introduction of novel, specific ligands in clinical practice, PET will play an ever stronger role in diagnosis, risk stratification, and monitoring of therapy.
引用
- Paschali AN, Nekolla SG, Evangelou K, et al. One Coin, No Need to Flip: Shared PET Targets in Cancer and Coronary Artery Disease. AJR Am J Roentgenol. 2016. PMID: 27897437. doi:10.2214/AJR.16.16599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。